1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Hantech Bio-Technology Co., Ltd.

Hantech Bio-Technology Co., Ltd.

TTPEX:1294
49.50
TWD
-0.10
(-0.20%)
3.86EPS
16.89P/E
2.39BMarket Cap
Nov 12Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.53
12.36
8.68
9.87
18.84
24.1
21.48
22.58
Basic EPS, GAAP
0.52
2.58
1.18
1.55
4.46
5.01
3.84
3.89
Free Cash Flow per Basic Share
1.76
0.32
-1.3
-0.67
-3.17
4.04
3.97
3.15
Dividend per Share
0.24
0.17
0.29
- -
0.51
0.63
2.41
- -
Book Value per Share
2.53
4.35
5.33
8.12
11.97
22.43
22.83
22.55
Tangible Book Value per Share
2.52
4.33
5.29
8.08
11.87
22.27
22.72
22.45
Basic Weighted Avg Shares
15
22
28
31
33
31
36
38
Sales/Revenue/Turnover
116
267
240
303
625
748
779
865
Operating Margin (%)
9.1
27.36
16.07
18.99
29.62
26.38
22.29
21.32
Depreciation Expense
12
15
19
19
21
32
38
39
Net Income, GAAP
8
56
33
47
148
156
139
149
Effective Tax Rate (%)
13
20.45
19.09
20.56
20.07
20.15
19.61
19.67
Profit Margin (%)
6.86
20.91
13.55
15.69
23.69
20.8
17.86
17.25
Working Capital
29
62
68
62
116
342
345
317
LT Debt
10
83
129
105
300
101
83
84
Total Equity
83
148
178
269
401
821
832
822
Return on Invested Capital (%)
- -
33.28
11.29
12.74
26.3
18.67
14.73
16
Return on Capital (%)
- -
34.13
12.75
14.38
27.6
19.58
15.29
16.75
Return on Common Equity (%)
- -
49.39
20.52
21.5
44.55
25.61
16.89
18.42

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
8
8
LT Borrowings
69
66
62
LT Finance Leases
14
24
22
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
2,385
2,425
2,388

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
592
608
633
Cash, Cash Equivalents & STI
339
354
374
Accounts Receivable, Net
130
127
136
Inventories
108
112
111
Total Current Liabilities
246
225
316
Payables & Accruals
- -
- -
- -
ST Debt
6
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
45.38%
1.39%
Free Cash Flow
- -
-90.34%
14.8%
Net Income, GAAP
- -
42.12%
-10.68%
Sales/Revenue/Turnover
- -
29.28%
4.02%
Total Cash Common Dividend
- -
- -
350.34%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
180
217
198
153
748
2025
175
194
196
214
779
2026
228
227
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.07
1.26
1.28
0.85
5.01
2025
0.89
0.88
0.83
1.03
3.84
2026
1.18
0.87
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.63
2025
- -
- -
- -
- -
2.41
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yulin Li
Full Time Employees
154
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 101, Gongye Rd. Yuanlin TX Taiwan 514
IPO Date
Sep 26, 2024
Website
htbios.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Hantech Bio-Technology Co., Ltd. manufactures and sells health supplement products, specializing in OEM and ODM services for biotech foods, functional beverages, and dietary supplements in Taiwan. The company produces dietary supplements in gel, liquid, powder, crystal jelly, and retort pouch forms; offers functional drinks such as collagen drinks, lutein drinks, iron-supplement drinks, probiotic drinks like Move-Free Revive and Daily Fight, and traditional Kampo care products including patented ultra-fine nano pearl powder and food-grade Guilu essence (tortoise shell and deer antler powder); provides raw materials like powder capsules and concentrated slurries; and delivers comprehensive services encompassing product concept development, formula design, unique raw material sourcing, dosage form selection, patented pouch packaging design, outer box creation, and backend marketing support. Hantech Bio-Technology operates primarily in Taiwan with product sales extending to China, Southeast Asia, America, and other regions, targeting diverse channels including direct sales, e-commerce, pharmacies, beauty shops, TV shopping, and live-stream platforms. Founded in 2007 and headquartered at No. 60, Zhongshan Road, Sec. 1, Yuanlin City, Taiwan, the company holds certifications including ISO22000, HACCP, GMP, SNQ national quality mark, and HALAL, and listed on the Taipei Exchange (TPEX: 1294) in September 2022.